Xinhua News Agency, Wuhan, February 5 (Reporters: Hu Zhe, Li Changzheng) Thanks to the support of the Ministry of Science and Technology, National Health Commission and National Medical Products Administration, among others, the antiviral drug Remdesivir has obtained the registration approval for clinical trial. The first cases are grouped and the medication will start on February 6 for patients with severe pneumonia due to the 2019-nCoV infection.

抗病毒药物瑞德西韦临床试验在武汉启动

摘自新华网

新华社武汉2月5日电（记者胡喆、黎昌政）在科技部、国家卫健委、国家药监局等多部门支持下，抗病毒药物瑞德西韦（remdesivir）已完成临床试验的注册审批工作，第一批病例入组工作也已就位。首批新型冠状病毒感染的肺炎重症患者2月6日接受用药。